In this CME article, explore the complexities of Parkinson disease, focusing on neuropsychiatric symptoms, their prevalence, and effective treatment strategies for improved patient care.

In an upcoming Clinical Consult program, thought leaders discuss the critical need for innovative and targeted treatments in managing major depressive disorder (MDD).

Patients with IDD present to EDs at nearly double the rate of those without IDD, facing unique challenges and increased wait times. Effective management involves psychiatric consultants, consideration of medical issues, and communication with family members to optimize care. Recommendations include optimizing the ED environment, utilizing local resources, and employing assistive tools to improve patient and staff experiences. Implementing these strategies can enhance empathy, improve outcomes, and

Cobenfy showed numerical improvement in schizophrenia symptoms but did not achieve statistical significance compared to placebo in the ARISE study. The trial underscored challenges in adjunctive treatment studies, including demonstrating benefits beyond established antipsychotics. Despite not meeting the primary endpoint, Cobenfy’s safety profile and potential benefits suggest further investigation is warranted. Cobenfy, approved by the FDA in 2024, offers a novel mechanism of action for schizophrenia